Registered title, quoted from ClinicalTrials.gov
Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China
An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page
- Study siteShandong Provincial Hospital山东省立医院JinanHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07842835, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 2
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (2 points)Hide the checklist
18 years to 100 years; sex: all
Registered eligibility fields
Scheduled to undergo needle biopsy or surgical resection of a lesion involving the brain, spinal cord, or meninges.
Inclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07842835, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- General Criteria for Patient Participants
- Age ≥18 years.
- Radiological findings suspicious for primary central nervous system lymphoma (PCNSL).
- Scheduled to undergo needle biopsy or surgical resection of a lesion involving the brain, spinal cord, or meninges.
- Willing and able to provide written informed consent.
- Core PCNSL Cohort
- Patient participants must additionally meet all of the following criteria:
- Histopathologically confirmed PCNSL.
- Able and willing to comply with scheduled study follow-up.
- Able to undergo magnetic resonance imaging examinations.
- Non-PCNSL Disease Control Cohort
- Patient participants must meet the following criterion:
- Initially suspected of having PCNSL based on imaging findings but ultimately diagnosed with a condition other than PCNSL by histopathological examination.
- Healthy Control Cohort
- Age ≥18 years.
- Eligible for recruitment as a healthy control according to the study screening procedures.
- Meets the prespecified matching requirements for the study cohorts.
- Willing and able to provide written informed consent.
- Additional Criteria for the Longitudinal CSF/Peripheral Blood Subcohort
- Participants entering this subcohort must additionally meet all of the following criteria:
- No contraindication to lumbar puncture, as determined by the study physician.
- Willing and able to undergo serial cerebrospinal fluid and peripheral blood collection.
- Provides separate explicit informed consent for longitudinal biospecimen collection.
- Final eligibility for all cohorts will be determined by the study investigator based on the participant's clinical condition, pathological findings, and relevant examination results.
Exclusion Criteria:
- Exclusion Criteria for Patient Cohorts
- PCNSL is suspected based on imaging findings, but no definitive histopathological diagnosis can be obtained.
- Estimated life expectancy of less than 3 months and, in the investigator's judgment, inability to complete the minimum required clinical data or biospecimen collection.
- Refusal to provide written informed consent or withdrawal of informed consent.
- Additional Exclusion Criteria for the Longitudinal CSF/Peripheral Blood Subcohort
- Participants will be excluded from research lumbar puncture if any of the following conditions are present:
- Severe coagulation disorder.
- Marked or severe intracranial hypertension.
- Evidence of, or substantial risk for, cerebral herniation.
- Spinal infection or central nervous system infection.
- Any other definite contraindication to lumbar puncture, as determined by the investigator.
Exclusion Criteria for Healthy Controls
- Presence of a severe systemic disease.
- Any condition that, in the investigator's judgment, makes the individual unsuitable for participation.
- Refusal to provide written informed consent or withdrawal of informed consent.
Quoted from ClinicalTrials.gov, NCT07842835, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07842835, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.